Blueprint Medicines Corporation (NASDAQ:BPMC) is reporting third quarter financial results on Thursday 29th October 2020, before market open.
According to analysts surveyed by Thomson Reuters, BPMC is expected to report 3Q20 income of $ 7.72 per share from revenue of $ 631.57 million.
For the full year, analysts anticipate top line of $ 635.65 million, while looking forward to income of $ 1.68 per share bottom line.
Previous Quarter Performance
Blueprint Medicines Corporation unveiled loss for the second quarter of $ 2.28 per share, from the revenue of $ 8.34 million. Wall street analysts are predicting, BPMC to report 2Q20 loss of $ 2.14 per share from revenue of $ 6.94 million. The bottom line results missed street analysts by $ 0.14 or 6.54 percent, at the same time, top line results outshined analysts by $ 1.40 million or 20.17 percent.
Stock Performance
Shares of Blueprint Medicines Corporation traded low $ -0.46 or -0.44 percent on Wednesday, reaching $ 104.63 with volume of 454.50 thousand shares. Blueprint Medicines Corporation has traded high as $ 106.50 and has cracked $ 101.55 on the downward trend
According to the previous trading day, closing price of $ 104.63, representing a 142.76 % increase from the 52 week low of $ 43.29 and a 1.32 % decrease over the 52 week high of $ 106.50.
The company has a market capital of $ 5.78 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Blueprint Medicines Corporation will be hosting a conference call at 8:30 AM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.blueprintmedicines.com
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies.
